African research identifies strong candidate for possible single-dose malaria cure
28 August 2012
A compound discovered by a UCT drug discovery programme has been selected by MMV for its potent activity against multiple points in parasite's lifecycle
|Big news: Prof Kelly Chibale (centre), here with Minister Naledi Pandor, speaks about the compound MMV390048 that he and international collaborators hope will lead to the development of a single-dose treatment for malaria.||Panel report: Dr Tim Wells, Prof Kelly Chibale, Minister Naledi Pandor, Dr Max Price and Dr Richard Gordon of the Technology Innovation Agency address the media at a press conference where they announced the development of the new compound.|
A recently discovered compound - named MMV390048 - from the aminopyridine class not only has the potential to become part of a single-dose cure for all strains of malaria, but might also be able to block transmission of the parasite from person to person, according to a research collaboration involving the Medicines for Malaria Venture (MMV), based in Switzerland, and the Drug Discovery and Development Centre (H3-D) at UCT.
This was announced at UCT today.
On the basis of initial results it was selected by MMV for further development - making it the first compound researched on African soil to enter preclinical development in partnership with MMV.
An African solution to save lives
Naledi Pandor, the Minister of Science & Technology, said: "This is a significant victory in the battle to alleviate the burden of disease in the subcontinent. Clearly the war on this disease is not yet won, but I am excited by the role that our excellent scientists have played in this milestone in finding a potential cure for malaria and possibly preventing its transmission. Congratulations to Professor Kelly Chibale and all involved. This is evidence of the world-class science being done in South Africa and the continent, and of the power of continental and international scientific collaboration in the multidisciplinary approaches that are essential in addressing the societal challenges of our time."
Dr Max Price, the vice-chancellor of UCT, said: "H3-D was founded at UCT in 2010 for this very purpose: to develop African expertise towards solving the health problems that beset the developing world. We trust this clinical candidate is the first of many contributions Professor Chibale and his team will be making to the advancement of international medicine."
H3-D identified a molecule, code named MMV390048, which was selected in July 2012 by MMV's Expert Scientific Advisory Committee for further development. The promising new compound shows potent activity against multiple points in the malaria parasite's lifecycle. This means it not only has the potential to become part of a single-dose cure for malaria but might also be able to block transmission of the parasite from person to person.
The aminopyridine series was initially identified by Griffith University scientists in Australia as part of MMV's extensive malaria screening campaign of around 6 million compounds. A team of scientists from H3-D, led by UCT Professor Kelly Chibale, further scrutinised and explored the antimalarial potential of the series. With parasitological, pharmacological and contract chemistry support from the Swiss Tropical and Public Health Institute (Switzerland), the Centre for Drug Candidate Optimization at Monash University (Australia) and Syngene (India) respectively, the H3-D team selected the most promising compounds from the series to be optimised and retested.
In just 18 months the team had identified and developed a candidate suitable for preclinical development.
Equipping the next generation of African scientists
"We are very excited that this promising compound, researched by African scientists, has been selected by MMV for further development," said Chibale, the founder and director of H3-D. "This is truly a proud day for African science and African scientists. Our team is hopeful that the compound will emerge from rigorous testing as an extremely effective medicine for malaria - a disease that accounts for 24% of total child deaths in sub-Saharan Africa. What is more, H3-D and MMV achieved MMV390048 as a clinical candidate in record time. In the process we have developed a unique model for successful technology platforms, and generic modern pharmaceutical industry expertise and skills, to discover drugs in potentially any disease area in Africa."
Dr Tim Wells, MMV's Chief Scientific Officer, said: "This is a great achievement and an excellent example of the quality of research that can be fostered in Africa. We look forward to seeing more exciting compounds emerge from Kelly's team and are proud to be collaborating with H3-D; not only is it conducting excellent science today, but it is also providing world-class training for the next generation of African scientists."
What is so unique and exciting about MMV390048
- It is very potent: it displayed a complete cure of animals infected with malaria parasites in a single dose given orally, and thus has the potential to cure millions of people.
- It is active against a wide panel of resistant strains of the malaria parasite.
- Developing the drug has made possible the training of more than 10 local scientists and cemented a strong relationship with an international partner.
- The clinical candidate is in line to enter clinical trials in late 2013.
View a video of Prof Kelly Chibale speaking about H3-D.